Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q4 2024 value amounting to $1.1 billion.
- Vertex Pharmaceuticals' Accumulated Depreciation & Amortization fell 1043.82% to $1.1 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 billion, marking a year-over-year decrease of 1043.82%. This contributed to the annual value of $1.1 billion for FY2024, which is 1043.82% down from last year.
- As of Q4 2024, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization stood at $1.1 billion, which was down 1043.82% from $1.2 billion recorded in Q4 2023.
- Vertex Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $1.2 billion during Q4 2023, with a 5-year trough of $790.6 million in Q4 2020.
- In the last 5 years, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $1.0 billion in 2022 and averaged $993.5 million.
- As far as peak fluctuations go, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization soared by 63928.61% in 2020, and later tumbled by 1043.82% in 2024.
- Vertex Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $790.6 million in 2020, then rose by 13.33% to $896.0 million in 2021, then grew by 14.65% to $1.0 billion in 2022, then increased by 15.73% to $1.2 billion in 2023, then dropped by 10.44% to $1.1 billion in 2024.
- Its Accumulated Depreciation & Amortization stands at $1.1 billion for Q4 2024, versus $1.2 billion for Q4 2023 and $1.0 billion for Q4 2022.